Exclusive: New preclinical data suggest Silexion’s SIL204 cancer treatment may expose KRAS-driven tumors to immune attack while reducing immune evasion. ✍️: @danyasaperstein

Exclusive: New preclinical data suggest Silexion’s SIL204 cancer treatment may expose KRAS-driven tumors to immune attack while reducing immune evasion. ✍️: @danyasaperstein Link SIL204 treatment may help immune system identify, attack KRAS-driven tumors, research finds - exclu This comes just after SIL204 advanced into Phase 2/3 clinical evaluation at the end of July, beginning its first clinical trial at Tel Aviv Sourasky Medical Center.